Inclusion Criteria:  Metastatic castration-resistant prostate cancer (mCRPC) with progression per any Prostate Cancer Working Group 3 (PCWG3) criterion (Prostate-specific antigen (PSA), clinical, or radiographic) Has never received any chemotherapy for prostate cancer. Current or prior receipt of at least one androgen-signaling inhibitors (ASI) (abiraterone, enzalutamide, apalutamide, or darolutamide), with progression on it. Eligible for docetaxel chemotherapy at any dose level (treating provider's discretion). Has an upcoming genitourinary (GU) medical oncology appointment (in-person, telephone, or Zoom video visit) at University of California, San Francisco (UCSF) within 7-60 days of enrollment, during which next-line treatment options are anticipated to be discussed (treating provider's discretion). 18 years of age or older. Able to read, speak, and write in English (the application is in English only) Has access to and ability to use an iOS or Android smartphone or tablet. For video visits only: has access to and ability to use a second device (e.g., desktop, laptop, smartphone, tablet, etc.) that will run a Zoom video visit. Patient's provider of the upcoming appointment in #5 agrees to be recorded.  Inclusion criteria (provider participants):  1. UCSF GU medical oncology providers (medical doctor (MD), nurse practitioner (NP), or physician's assistant (PA)), regardless of whether their patient was enrolled  Exclusion Criteria:  Lack of decision-making capacity to provide consent to this trial. Uncorrectable hearing or visual impairment hindering the ability to perform necessary tasks in the trial. Any neurocognitive or psychiatric disorder hindering the ability to perform necessary tasks in the trial. Prior participation in Mobile Health ElectroNic COnsultation REcording (mENCORE) (participants have already received the intervention).